Lungs in mixed connective tissue disease.

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Mixed connective tissue disease (MCTD) presents overlapping features of systemic lupus erythematosus (SLE), progressive systemic sclerosis (PSS), and polymyositis-dermatomyositis (PM-DM).
• A characteristic high titer of antinuclear antibody against nuclear ribonucleoprotein (nRNP) is found in MCTD patients' sera.
• Pleuropulmonary manifestations are frequent in MCTD, occurring in 20% to 85% of cases.

Purpose of the Study:

• To review the spectrum of pleuropulmonary complications in mixed connective tissue disease (MCTD).
• To highlight the significance of pulmonary vascular pathology, particularly pulmonary arterial hypertension (PAH), as a severe complication of MCTD.

Main Methods:

• Literature review of studies on mixed connective tissue disease (MCTD) and its pleuropulmonary manifestations.
• Analysis of reported cases and epidemiological data on respiratory involvement in MCTD patients.

Main Results:

• Common pleuropulmonary complications include pleural effusion, interstitial lung disease, pulmonary arterial hypertension (PAH), pulmonary vasculitis, and hypoventilatory failure.
• Pulmonary vascular disease leading to progressive PAH and cor pulmonale represents the most critical and potentially fatal complication.
• These respiratory issues in MCTD mirror those seen in SLE, PSS, and PM-DM.

Conclusions:

• Pleuropulmonary manifestations are a significant and common feature of mixed connective tissue disease (MCTD).
• Pulmonary arterial hypertension (PAH) is a serious, life-threatening complication that requires vigilant monitoring.
• Early recognition and management of these respiratory complications are crucial, as they can be clinically silent until severe outcomes occur.